clinical trial · NCT07613294
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
Eli Lilly and Company·phase3·not yet recruiting·n = 252
AtherosclerosisCardiovascular DiseasesLipoprotein(a)LepodisiranPlacebo
brief summary
Lipoprotein(a), also known as Lp(a), is a protein that carries cholesterol and proteins in your blood. People with high Lp(a) have a higher risk for heart disease. The main purpose of the study is to investigate how lepodisiran, compared to a placebo, affects the amount and type of plaque in the heart's vessels using an imaging technology known as Coronary Computed Tomography Angiography (CCTA) in adults who have high levels of Lp(a). Participation will last about 120 weeks.
started
May 1, 2026
primary completion
Apr 1, 2029
completion
Apr 1, 2029
last updated
May 29, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol